Search - tctmd.com

Displaying 261 - 280 of 407

Sort: Relevancy | Date

News Conference News TCT 2019

Portico Noninferior to Commercial TAVR Valves in IDE Study

Caitlin E. Cox

September 27, 2019

News Industry News

Intact Vascular Announces Positive One-Year Data from TOBA III Clinical Trial

September 27, 2019

News Conference News HFSA 2019

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

L.A. McKeown

September 16, 2019

News Conference News ESC 2019

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

Yael L. Maxwell

September 12, 2019

News Conference News ESC 2019

Stopped Early, DAPA Offers Insight on ICD Timing After STEMI

Shelley Wood

September 04, 2019

News Conference News ESC 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

Shelley Wood

September 01, 2019

News Conference News ESC 2019

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

Todd Neale

September 01, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Daily News

DAPA-HF: Dapagliflozin Scores a Win in Heart Failure

Todd Neale

August 20, 2019

News Daily News

‘Manageable’ Stroke Risk Seen With Electrical LAA Isolation

Todd Neale

August 19, 2019

News Industry News

Cardiac Dimensions Reaches 1,000 Implants Of Carillon® System, A Minimally Invasive Treatment For Functional Mitral Regurgitation

July 01, 2019

News Industry News

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

June 26, 2019

News Conference News ESC Heart Failure 2019

Device-Based Therapy Offers REPRIEVE From Decongestion in Acute HF: TARGET 1 and 2

Shelley Wood

May 25, 2019

News Conference News EuroPCR 2019

Clip-Based Tricuspid Repair Improves Regurgitation, Function, and Quality of Life: TRILUMINATE

Michael O'Riordan

May 22, 2019

News Industry News

Intact Vascular Announces US Launch of the Tack Endovascular System® and First Commercial Use

May 07, 2019

News Industry News

Intact Vascular’s Tack Endovascular System® Receives FDA Approval

April 16, 2019

News Conference News ACC 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

Shelley Wood

March 26, 2019

News Daily News

HF Admissions Decline, Non-CV Hospitalizations Rise After TAVR

L.A. McKeown

March 13, 2019

News Daily News

How HF Drugs Help and Harm Female Patients: A Call for Sex-Specific Reporting

Shelley Wood

February 26, 2019

News Daily News

Could RAS-Inhibitor Prescription After TAVR Improve 1-Year Outcomes?

Yael L. Maxwell

December 10, 2018

Advertisement

Portico Noninferior to Commercial TAVR Valves in IDE Study

Intact Vascular Announces Positive One-Year Data from TOBA III Clinical Trial

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

Stopped Early, DAPA Offers Insight on ICD Timing After STEMI

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

DAPA-HF: Dapagliflozin Scores a Win in Heart Failure

‘Manageable’ Stroke Risk Seen With Electrical LAA Isolation

Cardiac Dimensions Reaches 1,000 Implants Of Carillon® System, A Minimally Invasive Treatment For Functional Mitral Regurgitation

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

Device-Based Therapy Offers REPRIEVE From Decongestion in Acute HF: TARGET 1 and 2

Clip-Based Tricuspid Repair Improves Regurgitation, Function, and Quality of Life: TRILUMINATE

Intact Vascular Announces US Launch of the Tack Endovascular System® and First Commercial Use

Intact Vascular’s Tack Endovascular System® Receives FDA Approval

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

HF Admissions Decline, Non-CV Hospitalizations Rise After TAVR

How HF Drugs Help and Harm Female Patients: A Call for Sex-Specific Reporting

Could RAS-Inhibitor Prescription After TAVR Improve 1-Year Outcomes?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content